Oral treatment of mice, cutaneously infected with herpes simplex virus type 1 (HSV-1) (strain SC16), with the alpha-glucosidase 1 inhibitor 6-O-butanoyl castanospermine (MDL 28,574) produced a significant delay in lesion development and reduced the amount of virus recovered from the brain. Virus load in the brains of mice, whose treatment started 2 days prior to infection, was reduced approximately 100-fold when compared to untreated controls. Treatment initiated at the time of infection, while less effective than pre-treatment, nevertheless reduced virus recovery from the brain by 10-fold. Consistent with its antiviral activity, orally administered MDL 28,574 was rapidly incorporated by brain tissue and mice fed with compound over extended periods maintained relatively high levels of drug at this site.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/glycob/5.2.249 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine learning and molecular docking prediction of potential inhibitors against dengue virus.
Front Chem
December 2024
African Society for Bioinformatics and Computational Biology, Cape Town, South Africa.
Introduction: Dengue Fever continues to pose a global threat due to the widespread distribution of its vector mosquitoes, and . While the WHO-approved vaccine, Dengvaxia, and antiviral treatments like Balapiravir and Celgosivir are available, challenges such as drug resistance, reduced efficacy, and high treatment costs persist. This study aims to identify novel potential inhibitors of the Dengue virus (DENV) using an integrative drug discovery approach encompassing machine learning and molecular docking techniques.
View Article and Find Full Text PDFThe pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.
Parasit Vectors
October 2023
UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), World Health Organization, Geneva, Switzerland.
Article Synopsis
- The World Health Organization (WHO) laid out its objectives for controlling and eliminating neglected tropical diseases (NTDs) in a 2021-2030 roadmap, emphasizing the need for new treatment options and research.
- A review of current anti-infective drug developments reveals that the existing pipeline cannot meet all treatment needs for NTDs, and WHO allows for off-label drug use based on safety and efficacy.
- The article summarizes the lack of clinical research over the past decade on oral small-molecule drugs for numerous NTDs that are neither approved by regulatory authorities nor included in WHO strategies, identifying specific diseases and drugs that have not been thoroughly evaluated.
Molecular Docking Analysis of with Thromboxane A Receptor (TXAR) (6IIU) and Antiviral Molecules for Possible Dengue Complications.
Infect Disord Drug Targets
February 2023
AKT Memorial College of Engineering and Technology, Kallakurichi, India.
Objective: The present study is an in silico model of platelet amplification potential of Adhatoda vasica, which can be used to treat thrombocytopenia in dengue complications.
Methods: Docking studies have proved to be an essential tool that facilitates the structural diversity of natural products to be harnessed in an organized manner. In the present study, vasicine containing natural anti-dengue potential was subjected to docking studies using Schrodinger glides software (ver.
Murine models of dengue virus infection for novel drug discovery.
Expert Opin Drug Discov
April 2022
Laboratorio de Investigaciones Infectológicas y Biología Molecular, Infectología, Departamento de Medicina, Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina.
Introduction: Dengue virus (DENV) is the causative agent of the most prevalent human disease transmitted by mosquitoes in tropical and subtropical regions worldwide. At present, no antiviral drug is available and the difficulties to develop highly protective vaccines against the four DENV serotypes maintain the requirement of effective options for dengue chemotherapy.
Areas Covered: The availability of animal models that reproduce human disease is a very valuable tool for the preclinical evaluation of potential antivirals.
A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19.
Sci Rep
June 2021
Institute of Sustainable Processes, Universidad de Valladolid, Valladolid, Spain.
In this study we have developed a method based on Flux Balance Analysis to identify human metabolic enzymes which can be targeted for therapeutic intervention against COVID-19. A literature search was carried out in order to identify suitable inhibitors of these enzymes, which were confirmed by docking calculations. In total, 10 targets and 12 bioactive molecules have been predicted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!